Clinical Advisor6h
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Managed Healthcare Executive5h
Costs of Hemophilia With Inhibitors Are High, Warranting Better Management | AMCP Annual 2025
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...
Zacks Investment Research on MSN11h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
GlobalData on MSN16h
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...